Short snippets of DNA found in human brain tissue provide new insight into human cognitive function and risk for developing certain neurological diseases, according to researchers from the Departments of Psychiatry and Neuroscience at Mount Sinai School of Medicine. The findings are published in the November 20th issue of PLoS Biology.
There are nearly 40 million positions in the human genome with DNA sequences that are different than those in non-human primates, making the task of learning which are important and which are inconsequential a challenge for scientists. Rather than comparing these sequences strand by strand, Schahram Akbarian, MD, PhD, Professor of Psychiatry and Neuroscience at Mount Sinai School of Medicine, wanted to identify the crucial set of differences between the two genomes by looking more broadly at the chromatin, the structure that packages the DNA and controls how it is expressed.
They found hundreds of regions throughout the human genome which showed a markedly different chromatin structure in neurons in the prefrontal cortex, a brain region that controls complex emotional and cognitive behavior, compared to non-human primates. The findings of the study provide important insights for diseases that are unique to humans such as Alzheimer’s disease and autism.
“While mapping the human genome has taught us a great deal about human biology, the emerging field of epigenomics may help us identify previously overlooked or discarded sequences that are key to understanding disease,” said Dr. Akbarian. “We identified hundreds of loci that represent untapped areas of study that may have therapeutic potential.”
Dr. Akbarian and his research team isolated small snippets of chromatin fibers from the prefrontal cortex. Next, they analyzed these snippets to determine what genetic signals they were expressing. Many of the sequences with human-specific epigenetic characteristics were, until recently, considered to be “junk DNA” with no particular function.
Now, they present new leads on how the human brain has evolved, and a starting point for studying neurological diseases. For example, the sequence of DPP10—a gene critically important for normal human brain development—not only showed distinct human-specific chromatin structures different from other primate brains such as the chimpanzee or the macaque, but the underlying DNA sequence showed some interesting differences from two extinct primates—the Neanderthal and Denisovan, most closely related to our own species and also referred to as ‘archaic hominins’.
“Many neurological disorders are unique to human and are very hard as a clinical syndrome to study in animals, such as Alzheimer’s disease, autism, and depression,” said Dr. Akbarian. “By studying epigenetics we can learn more about those unique pieces of the human genome.”
The research team also discovered that several of these chromatin regions appear to physically interact with each other inside the cell nucleus, despite being separated by hundreds of thousands of DNA strands on the genome. This phenomenon of “chromatin looping” appears to control the expression of neighboring genes, including several with a critical role for human brain development.
“There is growing consensus among genome researchers that much of what was previously considered as ‘junk sequences’ in our genomes indeed could play some sort of regulatory role,” said Dr. Akbarian.
This study was supported by grants from the National Institutes of Health. Dr. Akbarian plans to do more epigenetic studies in other areas of the brain to see if there are additional chromatin regions that are unique to humans. They also plan to study the epigenomes of other mammals with highly evolved social behaviors such as elephants.
Dr. Akbarian joined Mount Sinai in July 2012. He is internationally known for his cutting-edge research on the epigenetic mechanisms of psychiatric disorders. He is a widely recognized expert in advanced chromatin tools—many of which were developed in his laboratory—in conjunction with mouse mutagenesis and behavioral models of mental illness to bridge molecular, cellular, and behavioral investigations. He is also a renowned authority on the epigenetic analysis of human brain tissue examined postmortem.
Prior to joining Mount Sinai, Dr. Akbarian was Director of the Brudnick Neuropsychiatric Research Institute. He received his medical and doctorate degrees from the Freie Universitaet Berlin. Dr. Akbarian completed his postdoctoral training in neuroscience at the University of California at Irvine and the Whitehead Institute, and his residency in psychiatry at Massachusetts General Hospital.